{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Barry H"],"funding":["Innovative Medicines Initiative"],"pagination":["e0011500"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11037528"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["18(4)"],"pubmed_abstract":["<h4>Background</h4>The exposure to parasites may influence the immune response to vaccines in endemic African countries. In this study, we aimed to assess the association between helminth exposure to the most prevalent parasitic infections, schistosomiasis, soil transmitted helminths infection and filariasis, and the Ebola virus glycoprotein (EBOV GP) antibody concentration in response to vaccination with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen in African and European participants using samples obtained from three international clinical trials.<h4>Methods/principal findings</h4>We conducted a study in a subset of participants in the EBL2001, EBL2002 and EBL3001 clinical trials that evaluated the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against EVD in children, adolescents and adults fro"],"journal":["PLoS neglected tropical diseases"],"pubmed_title":["Helminth exposure and immune response to the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen."],"pmcid":["PMC11037528"],"funding_grant_id":["grant agreement EBOVAC1 (grant nr. 115854), EBOVAC2 (grant nr. 115861) and EBOVAC3 (grant nr.800176)"],"pubmed_authors":["Tinto H","Meda N","Nouctara M","Lhomme E","Bockstal V","Surenaud M","Greenwood B","Lacabaratz C","Valea I","Robinson C","Barry H","Somda S","Thiebaut R"],"additional_accession":[]},"is_claimable":false,"name":"Helminth exposure and immune response to the two-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen.","description":"<h4>Background</h4>The exposure to parasites may influence the immune response to vaccines in endemic African countries. In this study, we aimed to assess the association between helminth exposure to the most prevalent parasitic infections, schistosomiasis, soil transmitted helminths infection and filariasis, and the Ebola virus glycoprotein (EBOV GP) antibody concentration in response to vaccination with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen in African and European participants using samples obtained from three international clinical trials.<h4>Methods/principal findings</h4>We conducted a study in a subset of participants in the EBL2001, EBL2002 and EBL3001 clinical trials that evaluated the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against EVD in children, adolescents and adults fro","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Apr","modification":"2026-06-01T19:58:36.243Z","creation":"2026-05-20T03:07:58.92Z"},"accession":"S-EPMC11037528","cross_references":{"pubmed":["38603720"],"doi":["10.1371/journal.pntd.0011500"]}}